Houston, Texas--(Newsfile Corp. - June 11, 2020) - Psychedelics may soon disrupt traditional medicine.
It's part of the reason Eight Capital estimate the total market for mental health treatment could be valued at up to $100 billion. "The addressable market is incredibly large, and we're still in the early innings of what any sort of psychedelic treatment could do to resolve some of these important issues," notes the firm, as quoted by Business Insider.
With plenty of clinical trials supporting psychedelic treatments, like psilocybin mushrooms for the treatment of obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, eating disorders, depression, anxiety, it's only a matter of time before big pharmaceutical companies begin to invest heavily, and incorporate psychedelics into their own drug pipelines.
Psilocybin may also help treat eating disorders and obesity, too.
That's because psilocybin activates serotonin receptors, or "nature's own appetite suppressant," as noted by Psychology Today. "This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight."
In short, psilocybin may be able to meet a very large unmet need for compounds that can potentially lead to safe weight loss, and help improve metabolic health for millions. After all, there's quite a large, demanding market.
Right now, according to the World Health Organization (WHO), obesity has tripled in size over the last 50 years. In 2016, they note, 1.9 billion adults were overweight around the world. Of those, 650 million were considered obese. Just in the U.S., nearly 34% of adults and up to 20% of children are obese. It's greatly out of control.
Psilocybin May be a Miracle Weight Loss Drug
In fact, Yield Growth Corp.'s (CSE: BOSS) (OTCQB: BOSQF) majority owned subsidiary NeonMind filed a U.S. provisional patent application in the U.S. for the invention relating to therapeutic administration of psilocybin or psilocin, combined with supportive therapeutic treatment for a patient to provide weight loss benefits and treatment for related health issues.
The provisional patent is for a proposed guided psychedelic psilocybin therapy protocol using psychotherapy prior to, during and after the psychoactive effects of the psilocybin are felt by the patient. The psychedelic assisted psychotherapy is designed to assist in gaining insights from positive psychedelic experiences, to be integrated into everyday life and to help plan, prepare and make sense of psychedelic experiences for a therapeutic result.
In addition, NeonMind has retained contract research organization Translational Life Sciences Inc. to design and plan an initial preclinical study using psilocybin which is anticipated to begin in the fall of 2020. The preclinical study is anticipated to provide data to design phase 2 human clinical trials to test psilocybin as a weight loss treatment. The phase 2 clinical trials are anticipated to begin in 2021, subject to receiving all required regulatory approvals.
For more information, visit the company's website at .
About MarijuanaStox
is a leading web destination for all cannabis related companies. Investors can also find current marijuana-related quality financial, medical, legal and social news. is a media agency in North America dedicated to the cannabis industry, helping companies that operate in the space to attract quality investors, working capital and real publicity. Since 2005, we have had public companies in the US and Canada have rely on us to grow and succeed.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with , is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of MarijuanaStox.com) and The Yield Growth Corp, Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for The Yield Growth Corp. We own ZERO shares of The Yield Growth Corp. Please for full disclaimer.
Contact Information:
2818047972
To view the source version of this press release, please visit
